Abstract
To evaluate the metabolic effects of first-line somatostatin analogues or surgery in acromegaly. Retrospective, comparative, 12-month follow-up. Two hundred and thirty one patients (123 men, age 47.32 ± 14.63 years) with active acromegaly, first line treatments were somatostatin analogues in 151 (65.4%) and surgery in 80 (34.6%). Metabolic syndrome (MS) parameters, glucose, insulin and GH during oral glucose tolerance test, stimulated insulin sensitivity by insulin sensitivity index (ISI Matsuda), early and total insulin-secretion rate by insulinogenic index and AUCINS, visceral adiposity function, expressed by visceral adipose index (VAI). Somatostatin analogues treatment improved all MS parameters and significantly reduced fasting glucose (P < 0.001), HbA1c (P = 0.014) and the prevalence of DM (P = 0.003) when disease control was achieved. Both somatostatin analogues and surgery improved ISI Matsuda (P < 0.001) and reduced AUCINS (P < 0.001) and VAI (P < 0.001 and P = 0.003, respectively). Only in controlled somatostatin analogues-treated patients a significant reduction in insulinogenic index (P = 0.010) was observed. ISI Matsuda showed a significant independent correlation with IGF-1 levels (β = −0.258; P = 0.001) and VAI score (β = −0.430; P < 0.001). VAI was independently correlated with IGF-1 (β = 0.183; P = 0.004). Both somatostatin analogues and surgery can safely be used as first-line therapy in acromegaly, without any untoward effects on glucose tolerance. The control of acromegaly is the main determinant of beneficial effects on general features of insulin sensitivity. VAI could represent an additional link between disease control and insulin sensitivity.
Similar content being viewed by others
References
Melmed S (2006) Medical progress: acromegaly. N Engl J Med 355:2558–2573
Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119(11):3189–3202
Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocr Rev 25:102–152
Giustina A, Casanueva FF, Cavagnini F, Chanson P, Clemmons D, Frohman LA, Gaillard R, Ho K, Jaquet P, Kleinberg DL, Lamberts SW, Lombardi G, Sheppard M, Strasburger CJ, Vance ML, Wass JA, Melmed S (2003) Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 26:1242–1247
Jayasena C, Comninos A, Clarke H, Donaldson M, Meeran K, Dhillo W (2011) The effects of long-term GH and IGF-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly. Clin Endocrinol (Oxf) 75:220–225
Colao A, Baldelli R, Marzullo P, Ferretti F, Ferone D, Gargiulo P, Petretta M, Tamburrano G, Lombardi G, Liuzzi A (2000) Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 85:193–199
Sherlock M, Woods C, Sheppard MC (2011) Medical therapy in acromegaly. Nat Rev Endocrinol 7(5):291–300
Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, von Werder K, Wass J, Giustina A, for the Acromegaly Treatment Consensus Workshop Participants’ (2002) Guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054–4058
Colao A, Auriemma RS, Lombardi G, Pivonello R (2011) Resistance to somatostatin analogs in acromegaly. Endocr Rev 32:247–271
Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J, SMS995B2401 Study Group (2007) A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 66(6):859–868
Alberti KGMM, Christensen SE, Christensen NJ, Hansen AP, Iversen J, Lundbaek K, Seyer-Hansen K, Orskov H (1973) Inhibition of insulin secretion by somatostatin. Lancet 2:1299–1301
Johansson C, Wisen O, Efendic S, Uvnas-Wallenstein K (1981) Effect of somatostatin on gastrointestinal propagation and absorption of oral glucose in man. Digestion 22:126–137
Steffin B, Gutt B, Bidlingmaier M, Dieterle C, Oltmann F, Schopohl J (2006) Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur J Endocrinol 155:73–78
Pereira AM, Biermasz NR, Roelfsema F, Romijn JA (2005) Pharmacologic therapies for acromegaly. A review of their effects on glucose metabolism and insulin resistance. Treat Endocrinol 4:43–53
Saitoh Y, Ohnishi T, Arita N (2000) Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 52:549–555
Karaca Z, Tanriverdi F, Elbuken G, Cakir I, Donmez H, Selcuklu A, Durak A, Dokmetas H, Colak R, Unluhizarci K, Kelestimur F (2011) Comparison of primary octreotide-LAR and surgical treatment in newly diagnosed patients with acromegaly. Clin Endocrinol (Oxf). doi:10.1111/j.1365-2265.2011.04106.x [Epub ahead of print]
Tzanela M, Vassiliadi DA, Gavalas N, Szabo A, Margelou E, Valatsou A, Vassilopoulos C (2011) Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues. Clin Endocrinol (Oxf). doi:10.1111/j.1365-2265.2011.03996.x [Epub ahead of print]
Ronchi CL, Varca V, Beck-Peccoz P, Orsi E, Donadio F, Baccarelli A, Giavoli C, Ferrante E, Lania A, Spada A, Arosio M (2006) Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab 91:121–128
Chen HS, Wu TE, Jap TS, Hsiao LC, Lin HD, Lee SH, Lin SH (2011) Effects of long-acting release octreotide on glucose homeostasis in acromegaly patients after trans-sphenoidal surgery. Horm Metab Res 43:433–439
Cambuli VM, Galdiero M, Mastinu M, Pigliaru F, Auriemma RS, Ciresi A, Pivonello R, Amato M, Giordano C, Mariotti S, Colao A, Baroni MG (2011) Glycometabolic control in acromegalic patients with diabetes: a study of the effects of different treatments for GH excess and for hyperglycaemia. J Endocrinol Invest [Epub ahead of print]
Colao A, Auriemma RS, Savastano S, Galdiero M, Grasso LF, Lombardi G, Pivonello R (2009) Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study. J Clin Endocrinol Metab 94:2907–2914
Colao A, Pivonello R, Galderisi M, Cappabianca P, Auriemma RS, Galdiero M, Cavallo LM, Esposito F, Lombardi G (2008) Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab 93:2639–2646
Colao A, Auriemma RS, Galdiero M, Cappabianca P, Cavallo LM, Esposito F, Grasso LF, Lombardi G, Pivonello R (2009) Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-years observational, open, prospective study. J Clin Endocrinol Metab 94:528–537
Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, Galluzzo A, For the AlkaMeSy Study Group (2010) Visceral Adiposity Index (VAI): a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 33:920–922
Colao A, Martino E, Cappabianca P, Cozzi R, Scanarini M, Ghigo E, The participants of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous medical Education) Study Group (2006) J Endocrinol Invest 29:1017–1020
Colao A, Lombardi G (1998) Growth hormone and prolactin excess. Lancet 352:1455–1461
Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S, Acromegaly Consensus Group (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95:3141–3148
American Association of Clinical Endocrinologists (2000) The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE system of intensive diabetes self-management—2000 update. Endocr Pract 6(1):43–84
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin in man. Diabetologia 28:412–419
Matsuda M, De Fronzo RA (2001) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 24:460–464
Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Jarvinen H, Van Haeften T, Renn W, Gerich J (2000) Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 23:295–301
Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF (1981) Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 12:235–246
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2001) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults: executive summary of the third report of the National Cholesterol Education Program (NCEP). J Am Med Assoc 285:2486–2497
Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526–529
Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancrajan I, Lombardi G (2001) Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86:2779–2786
Arosio M, Macchelli S, Rossi CM, Casati G, Biella O, Foglia G (1995) Effects of treatment with octreotide in acromegalic patients—a multicenter Italian study. Italian Multicenter Octreotide Study Group. Eur J Endocrinol 133:430–439
Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A, D’Amico E, Ferretti E, Baratta R, Liuzzi A, Trischitta V, Tamburrano G (2003) Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol 59:492–499
Sonksen PH, Greenwood FC, Ellis JP, Lowy C, Rutherford A, Nabarro JD (1967) Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment. J Clin Endocrinol Metab 27:1418–1430
Ho KK, Jenkins AB, Furler SM, Borkman M, Chisholm DJ (1992) Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin Endocrinol (Oxf) 36:271–279
Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A (2009) Effects of somatostatin analogs on glucose homeostasis: a meta-analysis acromegaly studies. J Clin Endocrinol Metab 94:1500–1508
Lorenzo C, Haffner SM, Stancáková A, Laakso M (2010) Relation of direct and surrogate measures of insulin resistance to cardiovascular risk factors in nondiabetic Finnish offspring of type 2 diabetic individuals. J Clin Endocrinol Metab 95:5082–5090
Bengtsson BA, Brummer RJ, Bosaeus I (1990) Growth hormone and body composition. Horm Res 33(Suppl 4):19–24
Clemmons DR (2002) Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly. Pituitary 5:181–183
Richelsen B (1997) Action of growth hormone in adipose tissue. Horm Res 48(Suppl 5):105–110
Yang S, Mulder H, Holm C, Eden S (2004) Effects of growth hormone on the function of beta-adrenoceptor subtypes in rat adipocytes. Obes Res 12:330–339
Freda PU, Shen W, Heymsfield SB, Reyes-Vidal CM, Geer EB, Bruce JN, Gallagher D (2008) Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. J Clin Endocrinol Metab 93:2334–2343
Unger RH, Scherer PE (2010) Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. Trends Endocrinol Metab 21:345–352
Garg A (2000) Lipodystrophies. Am J Med 108:143–152
Asilmaz E, Cohen P, Miyazaki M, Dobrzyn P, Ueki K, Fayzikhodjaeva G, Soukas AA, Kahn CR, Ntambi JM, Socci ND, Friedman JM (2004) Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. J Clin Invest 113:414–424
Acknowledgments
This study has been supported in part by grants of Italian Minister of Research (MIUR)”, no. 2003068735.
Conflict of interest
Annamaria Colao is recipient of unrestricted support from Ipsen, Novartis and Pfizer for studies in neuroendocrinology. The other authors have nothing to disclose.
Ethical standards
The authors declare that the experiments comply with the current Italian laws.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Giordano, C., Ciresi, A., Amato, M.C. et al. Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. Pituitary 15, 539–551 (2012). https://doi.org/10.1007/s11102-011-0365-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11102-011-0365-5